LEGEND BIOTECH USA INC. v. LIU

CourtDistrict Court, D. New Jersey
DecidedMarch 4, 2024
Docket2:23-cv-02965
StatusUnknown

This text of LEGEND BIOTECH USA INC. v. LIU (LEGEND BIOTECH USA INC. v. LIU) is published on Counsel Stack Legal Research, covering District Court, D. New Jersey primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
LEGEND BIOTECH USA INC. v. LIU, (D.N.J. 2024).

Opinion

NOT FOR PUBLICATION UNITED STATES DISTRICT COURT FOR THE DISTRICT OF NEW JERSEY

LEGEND BIOTECH USA INC., Plaintiff, Case No. 2:23-cv-02965-BRM-LDW v. AMENDED OPINION LIANXING LIU, Defendant. MARTINOTTI, DISTRICT JUDGE Before the Court is Plaintiff Legend Biotech USA’s (“Plaintiff”) Motion for Preliminary Injunction to compel Defendant Lianxing Liu (“Defendant”) to submit all devices, online accounts, and hard copy documents in his possession, custody, and control to a forensic vendor for forensic inspection. (ECF Nos. 29−31.) Defendant filed an opposition (ECF No. 40), and Plaintiff filed a reply (ECF No. 42). Having reviewed the submissions filed in connection with the Motion and having declined to hold oral argument pursuant to Federal Rule of Civil Procedure 78(b), for the reasons set forth below and for good cause having been shown, Plaintiff’s Motion for Preliminary

Injunction is GRANTED. I. BACKGROUND A. Factual History Plaintiff is a biotechnology company developing cell-editing therapies for cancer and other diseases based on DNA, RNA, plasmid, and amino acid sequences. (ECF No. 1 ¶¶ 3–6.) Plaintiff’s cell-editing therapies are known as CAR-T cell therapies. (Id. ¶ 6.) In order to protect proprietary information pertaining to the therapies, Plaintiff implements a variety of security measures, including Data Loss Prevention and Insider Threat Management applications to flag outgoing emails and file transfers which contain potentially proprietary or confidential information. (Id. ¶ 7.) When such information is flagged by the applications, it is then quarantined for further review. (Id.) Plaintiff also uses programs to sweep the internet for potential proprietary and confidential information. (Id.) All of Plaintiff’s employees must “read and agree to confidentiality obligations,

a code of conduct, a data protection policy, a data handling policy, and media retention and destruction policies as a condition of their employment.” (Id.) On August 25, 2021, Plaintiff sent Defendant an offer letter for employment, and Defendant began working for Plaintiff shortly thereafter. (Id. ¶ 14.) As part of Defendant’s onboarding, he signed an “Intellectual Property Rights Assignment, Non-Competition and Confidentiality Agreement” (id.) in which he agreed not to use Plaintiff’s confidential information without written consent (ECF No. 1-3 § 1.2), and to return Plaintiff’s documents and property upon request during his employment (id. § 5). Shortly after beginning his employment with Plaintiff, Defendant allegedly began emailing Plaintiff’s trade secrets and confidential information to his

personal Gmail account, lianxing.liu@gmail.com. (ECF No. 1 ¶ 18.) During his employment, he also engaged in conversations with other cell therapy companies competing with Plaintiff about alternative employment. (Id. ¶¶ 35–36.) On May 10, 2023, Plaintiff, through its Data Loss Prevention system, flagged a file Defendant had sent to his personal email account from his company email account. (Id. ¶ 19.) Plaintiff determined this file contained its trade secrets and confidential information, specifically, “ for [Plaintiff]’s proprietary for a clinical product candidate.” (Id.) The file was on Plaintiff’s vendor portal to which Defendant did not have download access. (Id.) Defendant titled the email sent to his personal email address as “Notes LL.docx.” (Id.) After this email was flagged, Plaintiff obtained email logs of all emails sent from Defendant’s company email account to his personal email account. (Id. ¶ 20.) These logs showed Defendant had sent confidential internal presentations, research data, to his personal email account. (Id. ¶ 21.) Plaintiff met virtually with Defendant on May 11, 2023 through a human resources representative, where

Defendant was asked to access his personal email account via his work laptop. (Id. ¶ 22.) Defendant claimed he did not know how to access his personal email account from his work laptop, which prompted Plaintiff’s IT representative to instruct Defendant on how to do this. (Id.) Defendant alleges that during this meeting, Plaintiff threatened criminal action against Defendant. (ECF No. 40 at 2–3.) Once Defendant gained access to his personal email account, Defendant showed the account to Plaintiff. (ECF No. 1 ¶ 22.) Plaintiff then directed him to run several searches within his personal email account for any emails sent from Plaintiff’s email domain. (Id.) The searches revealed more than one hundred emails containing confidential and trade secret data, and Plaintiff instructed Defendant to delete all confidential data discovered during the searches.

(Id.) During this meeting, Plaintiff also discovered Defendant was seeking employment with Plaintiff’s competitors by offering to help such competitors develop cell therapy businesses and products related to the trade secrets Defendant allegedly took. (ECF No. 31 at 8.) At the meeting, Plaintiff asked Defendant to share the desktop from his personal laptop to confirm Plaintiff’s confidential files were not saved locally on the computer. (Id. ¶¶ 23–24.) Defendant claimed he was unable to share the screen, leading Plaintiff to request Defendant bring his laptop to its Piscataway, New Jersey office on May 17, 2023. (Id. ¶¶ 24–26.) On May 17, 2023, Defendant produced his laptop to Plaintiff, and Plaintiff discovered the “trash” on the laptop was emptied on May 16, 2023, shortly after Plaintiff had requested Defendant bring his laptop to the office. (Id. ¶ 26.) At the meeting, Plaintiff searched Defendant’s personal email to confirm the documents deleted on May 11, 2023 were gone, and searched all files in the computer to confirm no files obviously belonged to Plaintiff. (Id.) Plaintiff found no files belonging to it, although certain files had been renamed. (Id.) On May 19, 2023, Plaintiff reclaimed Defendant’s work laptop, which underwent forensic

analysis. (Id. ¶ 27.) On May 22, 2023, Plaintiff reviewed all emails Defendant had sent from his company email account, finding more “non-public for [Plaintiff’s] proprietary therapeutic delivery platform, internal protocols for testing, and templates for further studies” were sent to his personal email account under titles such as “Notice.” (Id. ¶ 28.) On May 23, 2023, Plaintiff demanded Defendant produce his personal laptop and phone for imaging, and on May 24, 2023, Plaintiff imaged Defendant’s “Macbook Pro, his Apple iPhone 11 (including his WeChat and other messaging platform files), his personal Gmail account, his iCloudsync data, and his personal Google Drive account that is associated with his personal Gmail account.” (Id. ¶ 29.) During this meeting, Defendant was not represented by counsel or given an Upjohn warning1.

(ECF No. 40 at 8.) Forensic analysis also later revealed Defendant had photographs of Plaintiff’s potentially confidential information, and that he may possess additional devices with relevant data. (ECF No. 1 ¶ 38.) In particular, the analysis revealed “Defendant had stored on his personal iPhone multiple photos of [Plaintiff’s] slides marked as privileged, confidential, and for internal use only” among other documents stored on personal devices. (ECF No. 31 at 7–8.)

1 An Upjohn warning is given by corporate counsel to employees of the company to clarify that their representation is of the company, and not of the individual. Such warnings are generally given to notify individuals that privilege over communications between the company and the individual is held by the company. Heritage Pharm., Inc. v. Glazer, Civ. A. No. 16-8483, 2019 WL 9309180, at *3 n.1 (D.N.J. Mar. 1, 2019); Utesch v. Lannett Co., Inc., Civ. A. No. 16-5932, 2020 WL 7260775, at *8 n.5 (E.D. Pa. Dec. 9, 2020); In re Processed Eggs Prods. Antitrust Litig., MDL No.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Maryland v. Shatzer
559 U.S. 98 (Supreme Court, 2010)
Hoffman v. United States
341 U.S. 479 (Supreme Court, 1951)
Fisher v. United States
425 U.S. 391 (Supreme Court, 1976)
Doe v. United States
487 U.S. 201 (Supreme Court, 1988)
Bimbo Bakeries USA, Inc. v. Botticella
613 F.3d 102 (Third Circuit, 2010)
United States v. Frierson, Jerome
945 F.2d 650 (Third Circuit, 1991)
Frank E. Acierno v. New Castle County
40 F.3d 645 (Third Circuit, 1994)
United States v. Hubbell
530 U.S. 27 (Supreme Court, 2000)
National Reprographics, Inc. v. Strom
621 F. Supp. 2d 204 (D. New Jersey, 2009)
United States Ex Rel. DRC, Inc. v. Custer Battles, LLC
415 F. Supp. 2d 628 (E.D. Virginia, 2006)

Cite This Page — Counsel Stack

Bluebook (online)
LEGEND BIOTECH USA INC. v. LIU, Counsel Stack Legal Research, https://law.counselstack.com/opinion/legend-biotech-usa-inc-v-liu-njd-2024.